POS-132 TRIAL DESIGN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NARSOPLIMAB SAFETY AND EFFICACY IN IGA NEPHROPATHY (ARTEMIS-IGAN)

IgA nephropathy (IgAN) is a glomerular disease in which the lectin pathway of complement is activated by immune complex deposition on mesangial cells. Narsoplimab (OMS721) is a fully human IgG4 monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway. Narsoplimab was evaluated for the treatment of IgAN in a Phase 2 clinical trial (NCT02682407) and an interim analysis suggested a substantial and clinically meaningful therapeutic effect (Lafayette RA, et al.